We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
- Authors
Poston, Jacqueline N.; Fromm, Jonathan R.; Rasmussen, Heather A.; Shustov, Andrei R.; Libby, Edward N.; Smith, Stephen D.; Gooley, Ted; Gopal, Ajay K.
- Abstract
The article highlights the use of brentuximab vedotin (BV) for the treatment of CD30-bearing lymphomas. It mentions BV as single agent and approved for treatment of relapsed or refractory classical Hodgkin lymphoma (CHL) and also highlights the findings of study of a prospective, single-arm phase II clinical trial of dose-dense BV in patients with BV-resistant CD30-positive lymphoma.
- Subjects
IPILIMUMAB; PILOT projects; THROMBOPOIETIN receptors
- Publication
British Journal of Haematology, 2019, Vol 186, Issue 1, p159
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.15742